AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC
Top Cited Papers
- 28 June 2021
- journal article
- letter
- Published by Elsevier BV in The Lancet
- Vol. 398 (10296), 207-209
- https://doi.org/10.1016/s0140-6736(21)01462-8
Abstract
No abstract availableFunding Information
- Wellcome Trust
- The Francis Crick Institute
- Medical Research Council
- NIHR
- Cancer Research UK
- University College London Hospitals NHS Foundation Trust
This publication has 9 references indexed in Scilit:
- Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) VariantThe New England Journal of Medicine, 2021
- Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine doseScience, 2021
- mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infectionScience, 2021
- SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectivenessThe Lancet, 2021
- Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccinationThe Lancet, 2021
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infectionNature Medicine, 2021
- The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 PandemicInternational Journal of Molecular Sciences, 2020
- COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responsesNature, 2020
- Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trialThe Lancet, 2020